Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 450 of 1631 entries
View as:

In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control

Phase: N/A Priority: Normal
NCT ID: NCT03441568 Org: User:
Start: 09/26/18 End: 08/02/19 Due: 08/02/20

Regorafenib Post-marketing Surveillance

Phase: N/A Priority: Normal
NCT ID: NCT01843400 Org: User:
Start: 04/22/13 End: 11/14/16 Due: 11/14/17

Glucose Reduction by Early Acarbose Treatment in Basal Insulin

Phase: N/A Priority: Normal
NCT ID: NCT00970528 Org: User:
Start: 11/30/09 End: 03/31/12 Due: 03/31/13

Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)

Phase: N/A Priority: Normal
NCT ID: NCT01689376 Org: User:
Start: - End: - Due: -

Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.

Phase: N/A Priority: Normal
NCT ID: NCT00960258 Org: User:
Start: 07/01/09 End: 11/11/13 Due: 11/11/14

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03396250 Org: User:
Start: 02/12/18 End: 03/29/18 Due: 03/29/19

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Phase: N/A Priority: Normal
NCT ID: NCT05071729 Org: User:
Start: 10/14/21 End: 10/19/22 Due: 10/19/23

Study to Investigate the Effect of Missed Pills on Follicular Development in Two Application Regimens of SH T 00186 D

Phase: N/A Priority: Normal
NCT ID: NCT00673686 Org: User:
Start: 05/31/04 End: 02/28/05 Due: 02/28/06

A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05176496 Org: User:
Start: 11/30/21 End: 07/15/23 Due: 07/15/24

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Phase: N/A Priority: Normal
NCT ID: NCT02540954 Org: User:
Start: 09/29/15 End: 06/04/20 Due: 06/04/21

Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)

Phase: N/A Priority: Normal
NCT ID: NCT03002922 Org: User:
Start: 01/18/17 End: 01/28/17 Due: 01/28/18

Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Phase: N/A Priority: Normal
NCT ID: NCT03699176 Org: User:
Start: 10/27/18 End: 12/25/19 Due: 12/25/20

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

Phase: N/A Priority: Normal
NCT ID: NCT03458728 Org: User:
Start: 04/30/18 End: 02/01/23 Due: 02/01/24

Wellnara Post-marketing Surveillance in Japan

Phase: N/A Priority: Normal
NCT ID: NCT01401114 Org: User:
Start: 03/31/09 End: 09/30/14 Due: 09/30/15

Adalat XL vs Diltiazem on Proteinuria and Blood Pressure in Hypertensive Diabetic Patients

Phase: N/A Priority: Normal
NCT ID: NCT00713011 Org: User:
Start: 11/30/08 End: 03/31/09 Due: 03/31/10

A Study to Learn More About How Radium-223 Affects the Quality of Life of Colombian Patients With Prostate Cancer That Has Not Responded to Testosterone Lowering Treatment and Has Spread to the Bones, and to Better Understand Its Safety

Phase: N/A Priority: Normal
NCT ID: NCT04681144 Org: User:
Start: 04/08/21 End: 11/21/22 Due: 11/21/23

Regulatory Post Marketing Surveillance Study on YAZ

Phase: N/A Priority: Normal
NCT ID: NCT00998257 Org: User:
Start: 07/31/09 End: 11/30/11 Due: 11/30/12

Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)

Phase: N/A Priority: Normal
NCT ID: NCT02428985 Org: User:
Start: 06/29/15 End: 09/20/23 Due: 09/20/24

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting

Phase: N/A Priority: Normal
NCT ID: NCT03278262 Org: User:
Start: 09/01/17 End: 12/31/17 Due: 12/31/18

Survey on Belgian Patients Suffering From Irregular Heartbeat and Starting Treatment With a Drug to Prevent Blood Clots in Blood Vessels and the Heart. This Study is Also Called BELANCOS.

Phase: N/A Priority: Normal
NCT ID: NCT04183270 Org: User:
Start: 02/10/20 End: 12/31/20 Due: 12/31/21

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05537740 Org: User:
Start: 10/11/22 End: 05/04/27 Due: 05/04/28

Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)

Phase: N/A Priority: Normal
NCT ID: NCT01951625 Org: User:
Start: 11/29/13 End: 06/09/15 Due: 06/09/16

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Phase: N/A Priority: Normal
NCT ID: NCT06246643 Org: User:
Start: 01/24/24 End: 04/27/26 Due: 04/27/27

A Study to Learn More About How Safe Darolutamide is Under Real-world Conditions in Participants With Metastatic Hormone-Sensitive Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06010914 Org: User:
Start: 10/09/23 End: 01/31/27 Due: 01/31/28

A Study to Learn More About How Well Treatment With BAY2927088 Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Phase: N/A Priority: Normal
NCT ID: NCT06760819 Org: User:
Start: 02/13/25 End: 10/25/27 Due: 10/25/28